Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(25 sites)
United States
Orthopedic Institute for Children (UCLA), Los Angeles, California UC Davis Medical Center, Sacramento, California University of Colorado School of Medicine, Aurora, Colorado Hemophilia of Georgia Center for Bleeding & Clotting Disorders of Emory, Atlanta, Georgia Science 37, Inc., Morrisville, North Carolina Hemophilia Center of Western PA, Pittsburgh, Pennsylvania Vanderbilt University Medical Center, Nashville, Tennessee University of Texas Southwestern, Dallas, Texas Washington Center for Bleeding Disorders, Seattle, Washington Versiti Comprehensive Center for Bleeding Disorders, Milwaukee, Wisconsin Australia
Royal Brisbane & Women's Hospital, Queensland Haemophilia Centre, Herston, Queenland Austria
Medical University of Vienna, Vienna, Vienna Brazil
Centro de Hemoterapia e Hematologia do Rio de Janeiro HEMORIO, Rio de Janeiro, Rio de Janeiro Hemocentro Unicamp, Campinas, São Paulo Hospital das Clinicas - USP Endereco, São Paulo, São Paulo Canada
Hamilton Health Sciences Corporation, Hamilton, Ontario Queens University, Kingston, Ontario St. Michaels Hospital, Toronto, Ontario India
K J Somaiya Super Speciality Hospital & Research Centre, Sion, Mumbai South Africa
Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg United Kingdom
Queen Elizabeth Hospital Birmingham, Birmingham, Edgbaston University Hospital Southampton NHS Foundation Trust, Southampton, Hampshire Royal Free Hospital, London, London Royal London Hospital, Clinical Haematology Research, Whitechapel, London Imperial College Healthcare NHS Trust- Queen Charlotte's & Chelsea Hospital, London